News: The Latest
Press Releases
Load More PostsContact Information
GENERAL
BUSINESS DEVELOPMENT
MEDIA
Chris Railey
chris@tenbridgecommunications.com
INVESTORS
Sarah McCabe
Sarah.McCabe@sternir.com
Presentations
Poster Presentation: A novel bispecific BCA356 targeting tumor antigen CAIX conjugated to an attenuated IL-12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity
Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
November 2022
Webinar: Clinical Update on BCA101: Overview and Discussion of Newly Presented Data
Presented by Bicara Therapeutics
September 2022
Poster Presentation: A Phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid cancers
American Society of Clinical Oncology
June 2022
Poster Presentation: Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGF-β Signaling, as a novel single-agent immunotherapy
Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
November 2021
Digital Presentation: First-in-human Phase I study of the bifunctional EGFR/TGFβ fusion protein BCA101 in patients with EGFR-driven advanced solid cancers
American Society of Clinical Oncology
June 2021